Current pharmaceutical biotechnology2025,Vol.26Issue(2) :276-288.DOI:10.2174/0113892010296038240427050421

In vitro Antileishmanial Activity and In silico Molecular Modeling Studies of Novel Analogs of Dermaseptins S4 and B2

Houda Haddad Klinger Antonio da Franca Rodrigues Houcemeddine Othman Leiz Maria Costa Veras Raiza Raianne Luz Rodrigues Ines Ouahchi Bouraoui Ouni Amira Zaieri
Current pharmaceutical biotechnology2025,Vol.26Issue(2) :276-288.DOI:10.2174/0113892010296038240427050421

In vitro Antileishmanial Activity and In silico Molecular Modeling Studies of Novel Analogs of Dermaseptins S4 and B2

Houda Haddad 1Klinger Antonio da Franca Rodrigues 2Houcemeddine Othman 3Leiz Maria Costa Veras 4Raiza Raianne Luz Rodrigues 2Ines Ouahchi 5Bouraoui Ouni 6Amira Zaieri7
扫码查看

作者信息

  • 1. BIOLIVAL Laboratory, Higher Institute of Biotechnology of Monastir ISBM, University of Monastir, 5000 Monastir, Tunisia||Biochemistry Department, Faculty of Medicine, University of Sousse, 4002 Sousse, Tunisia
  • 2. Laboratory of Infectious Diseases, Ladic, Campus Ministro Reis Velloso, Federal University of Delta do Parnaiba, 64202-020
  • 3. Laboratory of Cytogenetics and Reproductive Biology, CHU Farhat Hached, 4000 Sousse, Tunisia
  • 4. Biodiversity and Biotechnology Research Center, BIOTEC, Federal University of Piaui, Parnaiba, PI, Brazil
  • 5. Biodiversity Cytogenetics, Molecular Genetics and Reproductive Biology, Farhat Hached University Hospital, 4000 Sousse, Tunisia
  • 6. Pharmacology department, Faculty of Medicine, University of Sousse, 4002 Sousse, Tunisia
  • 7. Biochemistry Department, Faculty of Medicine, University of Sousse, 4002 Sousse, Tunisia
  • 折叠

Abstract

Background: Leishmaniasis is responsible for approximately 65,000 annual deaths. Various Leishmania species are the predominant cause of visceral, cutaneous, or mucocutaneous leishmaniasis, affecting millions worldwide. The lack of a vaccine, emergence of resistance, and undesirable side effects caused by antileishmanial medications have prompted researchers to look for novel therapeutic approaches to treat this disease. Antimicrobial peptides (AMPs) offer an alternative for promoting the discovery of new drugs. Methods: In this study, we detail the synthesis process and investigate the antileishmanial activity against Leishmania (Viannia) braziliensis for peptides belonging to the dermaseptin (DS) family and their synthetic analogs. The MTT assay was performed to investigate the cytotoxicity of these peptides on the murine macrophage cell line RAW 264.7. Subsequently, we performed molecular modeling analysis to explore the structure-function correlation of the derivatives interacting with the parasitic membrane. Results: All examined derivatives displayed concentration-dependent antileishmanial effect at low concentrations. Their effectiveness varied according to the peptide's proprieties. Notably, peptides with higher levels of charge demonstrated the most pronounced activities. Cytotoxicity assays showed that all the tested peptides were not cytotoxic compared to the tested conventional drug. The structure-function relationships demonstrated that the charged N-terminus could be responsible for the antileishmanial effect observed on promastigotes. Conclusion: Collectively, these results propose that dermaseptins (DS) might offer potential as promising candidates for the development of effective antileishmanial therapies.

Key words

Dermaseptin B2/dermaseptin S4/analogs/Leishmania (Viannia) braziliensis/antileishmanial activity/promastigotes

引用本文复制引用

出版年

2025
Current pharmaceutical biotechnology

Current pharmaceutical biotechnology

SCI
ISSN:1389-2010
参考文献量82
段落导航相关论文